{"entity":{"type":"insider","cik":"0001434718","url":"/insider/0001434718","json_url":"/insider/0001434718.json","name":"Oliviero James F III","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":62,"n_filings":47,"first":"2009-05-22","last":"2025-04-03","span_basis":"filed_date"},"name_variants":[{"name":"Oliviero James F III","source":"filing","n_filings":47,"first_seen":"2009-05-22","last_seen":"2025-04-03"}],"transactions":[{"id":4592575,"accession":"0001104659-25-031813","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-031813","line_url":"/filing/0001104659-25-031813#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15090.0,"shares_display":"15,090","price_per_share":4.04,"price_display":"4.04","price_state":"stated","total_value":60963.6,"total_display":"60,963.60","total_whole":"60,964","shares_owned_after":3759929.0,"shares_owned_after_display":"3,759,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-02","filed_date":"2025-04-03","scope":"insider"},{"id":5043061,"accession":"0001104659-25-011656","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-25-011656","line_url":"/filing/0001104659-25-011656#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10331.0,"shares_display":"10,331","price_per_share":3.15,"price_display":"3.15","price_state":"stated","total_value":32542.65,"total_display":"32,542.65","total_whole":"32,543","shares_owned_after":3775019.0,"shares_owned_after_display":"3,775,019","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-11","scope":"insider"},{"id":5043055,"accession":"0001104659-25-011656","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-011656","line_url":"/filing/0001104659-25-011656#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9233.0,"shares_display":"9,233","price_per_share":3.41,"price_display":"3.41","price_state":"stated","total_value":31484.53,"total_display":"31,484.53","total_whole":"31,485","shares_owned_after":3785350.0,"shares_owned_after_display":"3,785,350","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-07","filed_date":"2025-02-11","scope":"insider"},{"id":2086495,"accession":"0001104659-24-130963","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-130963","line_url":"/filing/0001104659-24-130963#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":220230.0,"shares_display":"220,230","price_per_share":3.38,"price_display":"3.38","price_state":"stated","total_value":744377.4,"total_display":"744,377.40","total_whole":"744,377","shares_owned_after":3194583.0,"shares_owned_after_display":"3,194,583","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-19","filed_date":"2024-12-20","scope":"insider"},{"id":2086493,"accession":"0001104659-24-130963","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-130963","line_url":"/filing/0001104659-24-130963#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":602167.0,"shares_display":"602,167","price_per_share":3.87,"price_display":"3.87","price_state":"stated","total_value":2330386.29,"total_display":"2,330,386.29","total_whole":"2,330,386","shares_owned_after":3414813.0,"shares_owned_after_display":"3,414,813","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-18","filed_date":"2024-12-20","scope":"insider"},{"id":2837457,"accession":"0001104659-24-076442","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-076442","line_url":"/filing/0001104659-24-076442#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24610.0,"shares_display":"24,610","price_per_share":2.05,"price_display":"2.05","price_state":"stated","total_value":50450.5,"total_display":"50,450.50","total_whole":"50,451","shares_owned_after":1977170.0,"shares_owned_after_display":"1,977,170","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-26","filed_date":"2024-06-28","scope":"insider"},{"id":2471345,"accession":"0001104659-24-030149","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-030149","line_url":"/filing/0001104659-24-030149#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5894.0,"shares_display":"5,894","price_per_share":2.06,"price_display":"2.06","price_state":"stated","total_value":12141.64,"total_display":"12,141.64","total_whole":"12,142","shares_owned_after":350836.0,"shares_owned_after_display":"350,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-03-01","scope":"insider"},{"id":3117062,"accession":"0001104659-24-010265","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-010265","line_url":"/filing/0001104659-24-010265#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11900.0,"shares_display":"11,900","price_per_share":2.01,"price_display":"2.01","price_state":"stated","total_value":23919.0,"total_display":"23,919.00","total_whole":"23,919","shares_owned_after":369680.0,"shares_owned_after_display":"369,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider"},{"id":8472740,"accession":"0001104659-23-028603","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-23-028603","line_url":"/filing/0001104659-23-028603#line-3","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5483.0,"shares_display":"5,483","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":27415.0,"total_display":"27,415.00","total_whole":"27,415","shares_owned_after":144090.0,"shares_owned_after_display":"144,090","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-03","scope":"insider"},{"id":8472737,"accession":"0001104659-23-028603","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-028603","line_url":"/filing/0001104659-23-028603#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5548.0,"shares_display":"5,548","price_per_share":4.65,"price_display":"4.65","price_state":"stated","total_value":25798.2,"total_display":"25,798.20","total_whole":"25,798","shares_owned_after":134573.0,"shares_owned_after_display":"134,573","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-03-03","scope":"insider"},{"id":8198493,"accession":"0001104659-23-010771","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-010771","line_url":"/filing/0001104659-23-010771#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10261.0,"shares_display":"10,261","price_per_share":4.77,"price_display":"4.77","price_state":"stated","total_value":48944.97,"total_display":"48,944.97","total_whole":"48,945","shares_owned_after":182121.0,"shares_owned_after_display":"182,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-03","scope":"insider"},{"id":7890971,"accession":"0001104659-23-003529","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-003529","line_url":"/filing/0001104659-23-003529#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3817.0,"shares_display":"3,817","price_per_share":6.749,"price_display":"6.75","price_state":"stated","total_value":25760.933,"total_display":"25,760.93","total_whole":"25,761","shares_owned_after":192382.0,"shares_owned_after_display":"192,382","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-12","scope":"insider"},{"id":6307471,"accession":"0001104659-22-076976","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-22-076976","line_url":"/filing/0001104659-22-076976#line-4","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":1.11,"price_display":"1.11","price_state":"stated","total_value":16650.0,"total_display":"16,650.00","total_whole":"16,650","shares_owned_after":2562003.0,"shares_owned_after_display":"2,562,003","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-23","filed_date":"2022-07-01","scope":"insider"},{"id":6307468,"accession":"0001104659-22-076976","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-076976","line_url":"/filing/0001104659-22-076976#line-3","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":1.09,"price_display":"1.09","price_state":"stated","total_value":13080.0,"total_display":"13,080.00","total_whole":"13,080","shares_owned_after":2577003.0,"shares_owned_after_display":"2,577,003","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-22","filed_date":"2022-07-01","scope":"insider"},{"id":6307464,"accession":"0001104659-22-076976","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-076976","line_url":"/filing/0001104659-22-076976#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21000.0,"shares_display":"21,000","price_per_share":1.09,"price_display":"1.09","price_state":"stated","total_value":22890.0,"total_display":"22,890.00","total_whole":"22,890","shares_owned_after":2589003.0,"shares_owned_after_display":"2,589,003","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-21","filed_date":"2022-07-01","scope":"insider"},{"id":6307460,"accession":"0001104659-22-076976","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-076976","line_url":"/filing/0001104659-22-076976#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":228000.0,"shares_display":"228,000","price_per_share":1.09,"price_display":"1.09","price_state":"stated","total_value":248520.0,"total_display":"248,520.00","total_whole":"248,520","shares_owned_after":2610003.0,"shares_owned_after_display":"2,610,003","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-17","filed_date":"2022-07-01","scope":"insider"},{"id":6850933,"accession":"0001104659-22-049156","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-22-049156","line_url":"/filing/0001104659-22-049156#line-8","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21258.0,"shares_display":"21,258","price_per_share":1.51,"price_display":"1.51","price_state":"stated","total_value":32099.58,"total_display":"32,099.58","total_whole":"32,100","shares_owned_after":2838003.0,"shares_owned_after_display":"2,838,003","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-13","filed_date":"2022-04-22","scope":"insider"},{"id":6850930,"accession":"0001104659-22-049156","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001104659-22-049156","line_url":"/filing/0001104659-22-049156#line-7","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14030.0,"shares_display":"14,030","price_per_share":1.77,"price_display":"1.77","price_state":"stated","total_value":24833.1,"total_display":"24,833.10","total_whole":"24,833","shares_owned_after":2859261.0,"shares_owned_after_display":"2,859,261","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-05","filed_date":"2022-04-22","scope":"insider"},{"id":6850924,"accession":"0001104659-22-049156","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-22-049156","line_url":"/filing/0001104659-22-049156#line-6","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":86353.0,"shares_display":"86,353","price_per_share":1.79,"price_display":"1.79","price_state":"stated","total_value":154571.87,"total_display":"154,571.87","total_whole":"154,572","shares_owned_after":2873291.0,"shares_owned_after_display":"2,873,291","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-04","filed_date":"2022-04-22","scope":"insider"},{"id":4311557,"accession":"0001104659-21-013180","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-21-013180","line_url":"/filing/0001104659-21-013180#line-2","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48790.0,"shares_display":"48,790","price_per_share":3.4176,"price_display":"3.42","price_state":"stated","total_value":166744.704,"total_display":"166,744.70","total_whole":"166,745","shares_owned_after":3153210.0,"shares_owned_after_display":"3,153,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-05","scope":"insider"},{"id":4311553,"accession":"0001104659-21-013180","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-013180","line_url":"/filing/0001104659-21-013180#line-1","is_derivative":false,"issuer_cik":"0001434718","issuer_name":"Checkpoint Therapeutics, Inc.","issuer_ticker":"CKPT","issuer_name_source":null,"issuer_url":"/issuer/0001434718","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Director, Officer (CEO, President and Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, President and Director","security_title":"COMMON STOCK","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70000.0,"shares_display":"70,000","price_per_share":3.5075,"price_display":"3.51","price_state":"stated","total_value":245525.0,"total_display":"245,525.00","total_whole":"245,525","shares_owned_after":3202000.0,"shares_owned_after_display":"3,202,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-04","filed_date":"2021-02-05","scope":"insider"},{"id":8934394,"accession":"0000899243-15-000941","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-15-000941","line_url":"/filing/0000899243-15-000941#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1943.0,"shares_display":"1,943","price_per_share":9.61,"price_display":"9.61","price_state":"stated","total_value":18672.23,"total_display":"18,672.23","total_whole":"18,672","shares_owned_after":209406.0,"shares_owned_after_display":"209,406","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-06","filed_date":"2015-07-08","scope":"insider"},{"id":8719010,"accession":"0001209191-15-033264","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-033264","line_url":"/filing/0001209191-15-033264#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1878.0,"shares_display":"1,878","price_per_share":11.68,"price_display":"11.68","price_state":"stated","total_value":21935.04,"total_display":"21,935.04","total_whole":"21,935","shares_owned_after":169738.0,"shares_owned_after_display":"169,738","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-06","filed_date":"2015-04-08","scope":"insider"},{"id":8531758,"accession":"0001209191-15-002621","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-002621","line_url":"/filing/0001209191-15-002621#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5604.0,"shares_display":"5,604","price_per_share":13.79,"price_display":"13.79","price_state":"stated","total_value":77279.16,"total_display":"77,279.16","total_whole":"77,279","shares_owned_after":171616.0,"shares_owned_after_display":"171,616","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-05","filed_date":"2015-01-06","scope":"insider"},{"id":7020502,"accession":"0001209191-14-075121","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-075121","line_url":"/filing/0001209191-14-075121#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":15.69,"price_display":"15.69","price_state":"stated","total_value":392250.0,"total_display":"392,250.00","total_whole":"392,250","shares_owned_after":153345.0,"shares_owned_after_display":"153,345","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-10","filed_date":"2014-12-12","scope":"insider"},{"id":6272063,"accession":"0001209191-14-062374","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-062374","line_url":"/filing/0001209191-14-062374#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2694.0,"shares_display":"2,694","price_per_share":16.14,"price_display":"16.14","price_state":"stated","total_value":43481.16,"total_display":"43,481.16","total_whole":"43,481","shares_owned_after":153345.0,"shares_owned_after_display":"153,345","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-03","filed_date":"2014-10-07","scope":"insider"},{"id":6205038,"accession":"0001209191-14-057381","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-057381","line_url":"/filing/0001209191-14-057381#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":144237.0,"shares_display":"144,237","price_per_share":15.88,"price_display":"15.88","price_state":"stated","total_value":2290483.56,"total_display":"2,290,483.56","total_whole":"2,290,484","shares_owned_after":156039.0,"shares_owned_after_display":"156,039","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-08","filed_date":"2014-09-10","scope":"insider"},{"id":6414784,"accession":"0001209191-14-046590","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-046590","line_url":"/filing/0001209191-14-046590#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2054.0,"shares_display":"2,054","price_per_share":15.75,"price_display":"15.75","price_state":"stated","total_value":32350.5,"total_display":"32,350.50","total_whole":"32,351","shares_owned_after":300276.0,"shares_owned_after_display":"300,276","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-07-07","filed_date":"2014-07-09","scope":"insider"},{"id":6874255,"accession":"0001209191-14-026240","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-026240","line_url":"/filing/0001209191-14-026240#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2087.0,"shares_display":"2,087","price_per_share":16.46,"price_display":"16.46","price_state":"stated","total_value":34352.02,"total_display":"34,352.02","total_whole":"34,352","shares_owned_after":302330.0,"shares_owned_after_display":"302,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-04-03","filed_date":"2014-04-07","scope":"insider"},{"id":6376500,"accession":"0001209191-14-022560","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-14-022560","line_url":"/filing/0001209191-14-022560#line-6","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13444.0,"shares_display":"13,444","price_per_share":15.11,"price_display":"15.11","price_state":"stated","total_value":203138.84,"total_display":"203,138.84","total_whole":"203,139","shares_owned_after":304417.0,"shares_owned_after_display":"304,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-21","filed_date":"2014-03-21","scope":"insider"},{"id":6376498,"accession":"0001209191-14-022560","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-022560","line_url":"/filing/0001209191-14-022560#line-5","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":15.04,"price_display":"15.04","price_state":"stated","total_value":1880000.0,"total_display":"1,880,000.00","total_whole":"1,880,000","shares_owned_after":317861.0,"shares_owned_after_display":"317,861","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-20","filed_date":"2014-03-21","scope":"insider"},{"id":6376486,"accession":"0001209191-14-022560","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-022560","line_url":"/filing/0001209191-14-022560#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":154039.0,"shares_display":"154,039","price_per_share":15.23,"price_display":"15.23","price_state":"stated","total_value":2346013.97,"total_display":"2,346,013.97","total_whole":"2,346,014","shares_owned_after":442861.0,"shares_owned_after_display":"442,861","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-19","filed_date":"2014-03-21","scope":"insider"},{"id":6721845,"accession":"0001181431-14-001475","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-14-001475","line_url":"/filing/0001181431-14-001475#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6309.0,"shares_display":"6,309","price_per_share":12.57,"price_display":"12.57","price_state":"stated","total_value":79304.13,"total_display":"79,304.13","total_whole":"79,304","shares_owned_after":492861.0,"shares_owned_after_display":"492,861","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-03","filed_date":"2014-01-06","scope":"insider"},{"id":5394840,"accession":"0001181431-13-065072","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-065072","line_url":"/filing/0001181431-13-065072","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":79500.0,"shares_display":"79,500","price_per_share":12.62754716981132,"price_display":"12.63","price_state":"stated","total_value":1003890.0,"total_display":"1,003,890.00","total_whole":"1,003,890","shares_owned_after":476429.0,"shares_owned_after_display":"476,429","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-30","filed_date":"2013-12-31","scope":"insider","n_lines":2},{"id":5394836,"accession":"0001181431-13-065072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-065072","line_url":"/filing/0001181431-13-065072#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":12.68,"price_display":"12.68","price_state":"stated","total_value":380400.0,"total_display":"380,400.00","total_whole":"380,400","shares_owned_after":525929.0,"shares_owned_after_display":"525,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-27","filed_date":"2013-12-31","scope":"insider"},{"id":5171747,"accession":"0001181431-13-052946","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-052946","line_url":"/filing/0001181431-13-052946#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1475.0,"shares_display":"1,475","price_per_share":10.25,"price_display":"10.25","price_state":"stated","total_value":15118.75,"total_display":"15,118.75","total_whole":"15,119","shares_owned_after":555929.0,"shares_owned_after_display":"555,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-10-03","filed_date":"2013-10-07","scope":"insider"},{"id":5257920,"accession":"0001181431-13-039327","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-039327","line_url":"/filing/0001181431-13-039327#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1438.0,"shares_display":"1,438","price_per_share":7.95,"price_display":"7.95","price_state":"stated","total_value":11432.1,"total_display":"11,432.10","total_whole":"11,432","shares_owned_after":557404.0,"shares_owned_after_display":"557,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-05","filed_date":"2013-07-09","scope":"insider"},{"id":4449512,"accession":"0001181431-13-027758","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-027758","line_url":"/filing/0001181431-13-027758#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29363.0,"shares_display":"29,363","price_per_share":8.34,"price_display":"8.34","price_state":"stated","total_value":244887.42,"total_display":"244,887.42","total_whole":"244,887","shares_owned_after":558842.0,"shares_owned_after_display":"558,842","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-13","filed_date":"2013-05-14","scope":"insider"},{"id":5015946,"accession":"0001144204-13-020683","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-13-020683","line_url":"/filing/0001144204-13-020683#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1484.0,"shares_display":"1,484","price_per_share":6.93,"price_display":"6.93","price_state":"stated","total_value":10284.12,"total_display":"10,284.12","total_whole":"10,284","shares_owned_after":588205.0,"shares_owned_after_display":"588,205","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-04-05","filed_date":"2013-04-08","scope":"insider"},{"id":5015689,"accession":"0001144204-13-000856","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-13-000856","line_url":"/filing/0001144204-13-000856#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10859.0,"shares_display":"10,859","price_per_share":2.74,"price_display":"2.74","price_state":"stated","total_value":29753.66,"total_display":"29,753.66","total_whole":"29,754","shares_owned_after":589689.0,"shares_owned_after_display":"589,689","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-04","filed_date":"2013-01-04","scope":"insider"},{"id":3432285,"accession":"0001144204-12-055031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-12-055031","line_url":"/filing/0001144204-12-055031#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4973.0,"shares_display":"4,973","price_per_share":2.72,"price_display":"2.72","price_state":"stated","total_value":13526.56,"total_display":"13,526.56","total_whole":"13,527","shares_owned_after":567028.0,"shares_owned_after_display":"567,028","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-10-03","filed_date":"2012-10-05","scope":"insider"},{"id":3327447,"accession":"0001144204-12-038525","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-12-038525","line_url":"/filing/0001144204-12-038525#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4559.0,"shares_display":"4,559","price_per_share":1.99,"price_display":"1.99","price_state":"stated","total_value":9072.41,"total_display":"9,072.41","total_whole":"9,072","shares_owned_after":572001.0,"shares_owned_after_display":"572,001","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-03","filed_date":"2012-07-06","scope":"insider"},{"id":2789094,"accession":"0001144204-12-020459","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-12-020459","line_url":"/filing/0001144204-12-020459#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5458.0,"shares_display":"5,458","price_per_share":1.601,"price_display":"1.60","price_state":"stated","total_value":8738.258,"total_display":"8,738.26","total_whole":"8,738","shares_owned_after":176560.0,"shares_owned_after_display":"176,560","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-04-05","filed_date":"2012-04-05","scope":"insider"},{"id":2788913,"accession":"0001144204-12-000306","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-12-000306","line_url":"/filing/0001144204-12-000306#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7190.0,"shares_display":"7,190","price_per_share":2.625,"price_display":"2.62","price_state":"stated","total_value":18873.75,"total_display":"18,873.75","total_whole":"18,874","shares_owned_after":182018.0,"shares_owned_after_display":"182,018","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-01-03","filed_date":"2012-01-03","scope":"insider"},{"id":8860468,"accession":"0001144204-11-056628","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-11-056628","line_url":"/filing/0001144204-11-056628#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6105.0,"shares_display":"6,105","price_per_share":2.816,"price_display":"2.82","price_state":"stated","total_value":17191.68,"total_display":"17,191.68","total_whole":"17,192","shares_owned_after":161208.0,"shares_owned_after_display":"161,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-10-03","filed_date":"2011-10-05","scope":"insider"},{"id":9059222,"accession":"0001144204-11-039658","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-11-039658","line_url":"/filing/0001144204-11-039658#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4611.0,"shares_display":"4,611","price_per_share":4.8,"price_display":"4.80","price_state":"stated","total_value":22132.8,"total_display":"22,132.80","total_whole":"22,133","shares_owned_after":167313.0,"shares_owned_after_display":"167,313","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-07-05","filed_date":"2011-07-07","scope":"insider"},{"id":9023340,"accession":"0001144204-11-034757","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-11-034757","line_url":"/filing/0001144204-11-034757#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47231.0,"shares_display":"47,231","price_per_share":4.99,"price_display":"4.99","price_state":"stated","total_value":235682.69,"total_display":"235,682.69","total_whole":"235,683","shares_owned_after":171924.0,"shares_owned_after_display":"171,924","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-06-06","filed_date":"2011-06-08","scope":"insider"},{"id":9157447,"accession":"0001144204-11-020841","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-11-020841","line_url":"/filing/0001144204-11-020841#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4490.0,"shares_display":"4,490","price_per_share":5.1,"price_display":"5.10","price_state":"stated","total_value":22899.0,"total_display":"22,899.00","total_whole":"22,899","shares_owned_after":219155.0,"shares_owned_after_display":"219,155","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-04-05","filed_date":"2011-04-07","scope":"insider"},{"id":9059115,"accession":"0001144204-11-000205","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-11-000205","line_url":"/filing/0001144204-11-000205#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001434718","owner_name":"Oliviero James F III","owner_display_name":"Oliviero James F III","owner_url":"/insider/0001434718","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14064.0,"shares_display":"14,064","price_per_share":4.67,"price_display":"4.67","price_state":"stated","total_value":65678.88,"total_display":"65,678.88","total_whole":"65,679","shares_owned_after":223645.0,"shares_owned_after_display":"223,645","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-01-03","filed_date":"2011-01-03","scope":"insider"}],"collapsed":true,"next_cursor":"2011-01-03|9059115","ledger_fault":false,"count":{"value":62,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":60,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":62},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001651407","name":"Checkpoint Therapeutics, Inc.","url":"/issuer/0001651407","role":"Director, Officer (CEO, President and Director)","n_filings":12,"first_seen":"2021-02-05","last_seen":"2025-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001114220","name":"KERYX BIOPHARMACEUTICALS INC","url":"/issuer/0001114220","role":"Officer (Chief Financial Officer)","n_filings":35,"first_seen":"2009-05-22","last_seen":"2015-07-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001434718","retrieved_at":"2026-08-26T13:48:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}